Zacks Research Has Optimistic View of Immunovant Q3 Earnings

by · The Cerbat Gem

Immunovant, Inc. (NASDAQ:IMVT – Free Report) – Research analysts at Zacks Research upped their Q3 2026 earnings per share estimates for shares of Immunovant in a research note issued on Thursday, December 18th. Zacks Research analyst Team now forecasts that the company will earn ($0.76) per share for the quarter, up from their previous estimate of ($0.77). The consensus estimate for Immunovant’s current full-year earnings is ($2.69) per share. Zacks Research also issued estimates for Immunovant’s Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($2.91) EPS, Q3 2027 earnings at ($0.89) EPS, Q4 2027 earnings at ($0.67) EPS, FY2027 earnings at ($3.05) EPS, Q1 2028 earnings at ($0.73) EPS, Q2 2028 earnings at ($0.70) EPS and FY2028 earnings at ($2.68) EPS.

Several other brokerages also recently issued reports on IMVT. JPMorgan Chase & Co. cut their target price on shares of Immunovant from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, September 30th. Truist Financial assumed coverage on Immunovant in a research note on Tuesday, October 14th. They issued a “hold” rating and a $16.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Immunovant in a research note on Thursday, September 4th. Guggenheim reissued a “buy” rating and set a $41.00 target price on shares of Immunovant in a report on Thursday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immunovant in a research note on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immunovant has a consensus rating of “Moderate Buy” and a consensus price target of $27.63.

Check Out Our Latest Report on IMVT

Immunovant Price Performance

Shares of IMVT opened at $27.54 on Monday. The company has a market cap of $4.83 billion, a PE ratio of -9.70 and a beta of 0.56. The firm has a 50-day moving average of $22.89 and a 200-day moving average of $18.55. Immunovant has a one year low of $12.72 and a one year high of $27.69.

Immunovant (NASDAQ:IMVT – Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.01). During the same period last year, the business posted ($0.74) EPS.

Insider Activity at Immunovant

In other Immunovant news, Director Andrew J. Fromkin sold 22,249 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $23.25, for a total transaction of $517,289.25. Following the transaction, the director owned 85,852 shares in the company, valued at $1,996,059. This trade represents a 20.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Douglas J. Hughes sold 15,000 shares of Immunovant stock in a transaction on Monday, December 1st. The stock was sold at an average price of $23.24, for a total value of $348,600.00. Following the sale, the director directly owned 120,773 shares of the company’s stock, valued at $2,806,764.52. This represents a 11.05% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 68,660 shares of company stock valued at $1,599,001 in the last 90 days. Corporate insiders own 1.80% of the company’s stock.

Hedge Funds Weigh In On Immunovant

Hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. boosted its holdings in Immunovant by 11.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 626,612 shares of the company’s stock valued at $10,709,000 after purchasing an additional 62,170 shares during the period. Nuveen LLC acquired a new stake in shares of Immunovant in the first quarter valued at approximately $3,999,000. Northern Trust Corp raised its position in shares of Immunovant by 1.8% in the first quarter. Northern Trust Corp now owns 536,622 shares of the company’s stock valued at $9,171,000 after buying an additional 9,255 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Immunovant in the first quarter valued at approximately $37,000. Finally, AlphaQuest LLC grew its position in Immunovant by 1,510.2% during the first quarter. AlphaQuest LLC now owns 5,700 shares of the company’s stock worth $97,000 after buying an additional 5,346 shares in the last quarter. 47.08% of the stock is owned by institutional investors.

Immunovant Company Profile

(Get Free Report)

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.

Featured Stories